High affinity antibody antagonists of interleukin-13 receptor alpha 1

Details for Australian Patent Application No. 2007319604 (hide)

Owner CSL Limited

Inventors An, Zhiqiang; Zaller, Dennis; Nash, Andrew Donald; Strohl, William R.; Baca, Manuel; Fabri, Louis Jerry

Agent FB Rice

Pub. Number AU-B-2007319604

PCT Pub. Number WO2008/060813

Priority 60/852,884 19.10.06 US

Filing date 19 October 2007

Wipo publication date 22 May 2008

Acceptance publication date 24 March 2011

International Classifications

C07K 16/18 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies - against material from animals or humans

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61P 43/00 (2006.01) Drugs for specific purposes, not provided for in groups

C12N 15/00 (2006.01) Mutation or genetic engineering

C12N 15/11 (2006.01) Mutation or genetic engineering - DNA or RNA fragments

Event Publications

11 June 2009 PCT application entered the National Phase

  PCT publication WO2008/060813 Priority application(s): WO2008/060813

21 January 2010 Alteration of Name

  The name of the applicant has been altered to CSL Limited; Merck Sharp & Dohme Corp.

16 September 2010 Assignment before Grant

  Merck Sharp & Dohme Corp.; CSL Limited The application has been assigned to CSL Limited

24 March 2011 Application Accepted

  Published as AU-B-2007319604

21 July 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007319605-Anti-IL-13R alpha 1 antibodies and their uses thereof

2007319603-Dynamic gaming library